Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial

Lindsay, James O; Hind, Daniel; Swaby, Lizzie; Berntsson, Hannah; Bradburn, Mike; Bannur C, Uday; Byrne, Jennifer; Clarke, Christopher; Desoysa, Lauren; Dickins, Ben; Din, Shahida; Emsley, Richard; Foulds, Gemma A; Gribben, John; Hawkey, Christopher; Irving, Peter M; Kazmi, Majid; Lee, Ellen; Loban, Amanda; Lobo, Alan; Mahida, Yashwant; Moran, Gordon W; Papaioannou, Diana; Parkes, Miles; Peniket, Andrew; Pockley, A Graham; Satsangi, Jack; Subramanian, Sreedhar; Travis, Simon; Turton, Emily; Uttenthal, Ben; Rutella, Sergio; Snowden, John A

doi:10.1016/s2468-1253(23)00460-0

Research Repository

All Outputs (2)

Case Series: Efficacy of Polyclonal Intravenous Immunoglobulin for Refractory Clostridioides difficile Infection (2024)
Journal Article

Background: Intravenous immunoglobulin (IVIg) for Clostridioides difficile infection (CDI) no longer features in treatment guidelines. However, IVIg is still used by some clinicians for severe or recurrent CDI (rCDI) cases. The main objective of this... Read More about Case Series: Efficacy of Polyclonal Intravenous Immunoglobulin for Refractory Clostridioides difficile Infection.

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial (2024)
Journal Article

Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy... Read More about Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.